| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698137 | Clinical Oncology | 2017 | 7 Pages |
Abstract
For Child-Pugh A patients with good performance status, survival outcomes were similar to those reported in global randomised controlled trials. Patients with ALBI grade > 1, Child-Pugh B or poor performance status seem to derive limited benefit from sorafenib treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
J. King, D.H. Palmer, P. Johnson, P. Ross, R.A. Hubner, K. Sumpter, S. Darby, C. Braconi, C. Iwuji, D. Swinson, P. Collins, K. Patel, J. Nobes, I. Muazzam, C. Blesing, A. Kirkwood, S. Nash, T. Meyer,